Targeting Interferon Regulatory Factor for Cardiometabolic Diseases: Opportunities and Challenges

Curr Drug Targets. 2017;18(15):1754-1778. doi: 10.2174/1389450116666150804110412.


Background: The pathological activation of innate immune system may contribute to the development of cardiometabolic diseases. The interferon regulatory factor (IRF) family members, which are the major transcription factors in innate immune signaling, are implicated in cardiometabolic diseases.

Objective: The aim of this review is to summary the current knowledge of the biological functions of IRFs in innate immune responses and immune cell development, and highlight our contemporary understanding of the functions and molecular mechanisms of IRFs in metabolic diseases, cardiovascular remodeling, and stroke.

Results: IRFs are the essential regulators of cardiometabolic diseases via immune-dependent and - independent manners.

Conclusion: IRFs signaling is the promising target to manage the initiation and progression of cardiometabolic disorders.

Keywords: Interferon regulatory factor signaling; cardiac remodeling; metabolic diseases; stroke; vascular injury; vascular remodeling.

Publication types

  • Review

MeSH terms

  • Animals
  • Cardiovascular Diseases / drug therapy
  • Cardiovascular Diseases / metabolism*
  • Disease Models, Animal
  • Humans
  • Immunity, Innate
  • Interferon Regulatory Factors / chemistry
  • Interferon Regulatory Factors / metabolism*
  • Metabolic Diseases / drug therapy
  • Metabolic Diseases / metabolism*
  • Molecular Targeted Therapy
  • Signal Transduction


  • Interferon Regulatory Factors